1. Cell Cycle/DNA Damage
  2. Cyclin G-associated Kinase (GAK)

Cyclin G-associated Kinase (GAK)

Cyclin G-associated kinase (GAK), also known as auxilin 2, is a cellular serine/threonine kinase. GAK was originally identified as an association partner of cyclin G and CDK5 (cyclin-dependent kinase 5). It is essential for clathrin trafficking, mediating binding of clathrin to the plasma membrane and the trans-Golgi network, and regulating receptor signalling by influencing trafficking downstream of clathrin-coated vesicles. GAK has been reported to phosphorylate the μ2 subunit of adaptor protein 1 and 2 (AP-1 and AP-2), thereby initiating a conformational change and enhancing their binding to sorting signals (in the form of tyrosineor dileucine-based motifs) within the cargo. In addition to its role in the cytoplasm, GAK has important functions in the nucleus. It is required for the maintenance of proper centrosome maturation and progression through mitosis. GAK plays a central role during development and GAK KO mice die early in gestation.

Cyclin G-associated Kinase (GAK) Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-101290A
    BMT-090605 hydrochloride Inhibitor 99.09%
    BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain[1].
  • HY-117626
    LP-935509 Inhibitor 99.74%
    LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research[1].
  • HY-122186
    SGC-GAK-1 99.77%
    SGC-GAK-1 is a potent, selective cyclin G-associated kinase (GAK) inhibitor with a Ki of 3.1 nM. SGC-GAK-1 is a chemical probe for GAK[1].
  • HY-148062
    RSS0680 98.03%
    RSS0680 (Example 22) is a bifunctional compound targeted protein degradation of kinases. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used for research of disease or disorder mediated by aberrant kinase activity[1].
  • HY-112486
    TA-316 98.19%
    TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells[1][2].
  • HY-112486G
    TA-316 (GMP) Agonist
    TA-316 GMP (Megakaryocytes/platelets inducing agent GMP) is a chemically synthesized c-MPL (thrombopoietin receptor) agonist (CMA). TA-316 GMP promotes platelet production, and its activity is comparable to that of recombinant human thrombopoietin (rhTPO) in some respects. TA-316 GMP acts by binding to the c-MPL receptor, activating related signaling pathways such as JAK/STAT, MAPK, and PI3K/AKT, which are critical for the proliferation and maturation of megakaryocytes (MKs, platelet precursors). TA-316 GMP also specifically upregulates the expression of vascular endothelial growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2) both of which are associated with megakaryocyte maturation and platelet production. TA-316 GMP can be used in the study of platelet amplification[1].
  • HY-147258A
    Culmerciclib maleate Inhibitor 99.52%
    Culmerciclib maleate (TQB3616 maleate) is a cyclin dependent kinase (CDK) inhibitor, and has antineoplastic activity[1].
  • HY-148061
    DB1113 99.28%
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity[1].
  • HY-114569
    6-CEPN Inhibitor 99.17%
    6-CEPN is a RAS inhibitor. 6-CEPN can inhibit RAS activation by binding to Icmt binding sites. 6-CEPN has anticancer activity. 6-CEPN can block cancer cells in the G1 phase. 6-CEPN can induce autophagy and necrosis of Cancer cells (Icmt: isovalerylcysteine carboxymethyltransferase)[1].
  • HY-147258
    Culmerciclib Inhibitor 98.09%
    Culmerciclib (TQB3616) is a cyclin dependent kinase (CDK) inhibitor, and has antineoplastic activity[1].
  • HY-124793A
    GAK inhibitor 49 hydrochloride 99.52%
    GAK inhibitor 49 hydrochloride is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 hydrochloride also shows binding to RIPK2[1].
  • HY-101290
    BMT-090605 Inhibitor
    BMT-090605 is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 can be used for the research of neuropathic pain[1].
  • HY-N2128
    Nigakinone 99.95%
    Nigakinone is one of the most abundant alkaloids responsible for the major pharmacological activities of Kumu.
  • HY-124793
    GAK inhibitor 49 98.79%
    GAK inhibitor 49 is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 also shows binding to RIPK2[1].